Pharmacoproteomics applications for drug target discovery in CNS disorders

Current Pharmacogenomics and Personalized Medicine

Volumn 9, Issue 2, 2011, Pages 102-122

  Park, Seyeon ^a  

^a Dongduk Women's University   (South Korea)

Author keywords

CNS; Diagnostic medicine; Drug targets; Personalized medicine; Pharmacoproteomic

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; APOMORPHINE; ARIPIPRAZOLE; BROMOCRIPTINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CX 614; ESCITALOPRAM; FLUOXETINE; GAMBOGIC ACID; HALOPERIDOL; LEVODOPA; LITHIUM; MEMANTINE; N [2 [4 (3 THIENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; OLANZAPINE; PALIPERIDONE; PERGOLIDE; QUETIAPINE; RILUZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VOFOPITANT;

ACUPUNCTURE; ALCOHOLISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANESTHESIA; AUTISM; BIPOLAR DISORDER; BULIMIA; CALCIUM HOMEOSTASIS; CELL FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; COCAINE DEPENDENCE; COGNITIVE DEFECT; DEPRESSION; DISEASE MARKER; DOWN REGULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DYSKINESIA; ELECTROCONVULSIVE THERAPY; EPILEPSY; HUMAN; MAJOR DEPRESSION; MANIA; MOLECULAR DYNAMICS; MOOD DISORDER; NEURAL STEM CELL; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OLIGODENDROGLIA; OXIDATIVE STRESS; PARKINSON DISEASE; PHARMACOGENOMICS; PHOSPHOLIPID METABOLISM; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEOMICS; QUALITATIVE RESEARCH; REVIEW; SCHIZOPHRENIA; SEIZURE; SIGNAL TRANSDUCTION; STROKE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALIA;

EID: 79955677442     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569211795508484     Document Type: Review

References (210)

1. Korolainen MA, Nyman TA, Aittokallio T, et al. An update on clinical proteomics in Alzheimer's research. J Neurochem 2010;112: 1386-414.
2. Keller JN. Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Res Rev 2006; 5: 1-13.
3. Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-204.
4. Altar CA, Vawter MP, Ginsberg SD. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 2009; 34(1): 18-54.
5. Paschen W. Role of calcium in neuronal cell injury: which subcellular compartment is involved? Brain Res Bul 2000; 53: 409-13.
6. Mariani E, Polidori MC, Cherubini A, et al. Oxidative stress inbrain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 827: 65-75.
7. Pereira C, Agostinho P, Moreira PI, et al. Alzheimer's diseaseassociated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord 2005; 4: 383-403.
8. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer'sdisease. J Neuroimmunol 2007; 184: 69-91.
9. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer'sdisease. J Neurochem 2008; 104: 1433-9.
10. Alex ER, Chera LM, Lucia IS, et al. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009; 14(7): 493-501.
11. Mattila KM, Frey H. Alzheimer brain proteins investigated by twodimensionalgel electrophoresis with immobilized pH gradients in the first dimension. Electrophoresis 1994; 15: 721-5.
12. Yuliya VS, John D, Jared AB, et al. Human Alzheimer's diseasesynaptic O-GlcNAc site mapping and iTRAQ expression proteomicswith ion trap mass spectrometry. Amino Acids 2011;40(3): 765-79.
13. Virginie L, Enikö K, Denis FH, et al. Proteomics in human Parkinson's disease research. J Proteomics 2009; 73(1): 10-29.
14. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synucleinin cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006; 349:162-6.
15. Waragai M, Wei J, Fujita M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006; 345: 967-72.
16. Harrington MG, Merril CR. Two-dimensional electrophoresis and "ultrasensitive" silver staining of cerebrospinal fluid proteins inneurological diseases. Clin Chem 1984; 30: 1933-7.
17. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006;9: 293-348.
18. Goldknopf IL, Sheta EA, Bryson J, et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun 2006; 342:1034-9.
19. Basso M, Giraudo S, Corpillo D, et al. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004; 4: 3943-52.
20. Gabriele J, Pontoriero GF, Thomas N, et al. Cloning, characterization,and functional studies of a human 40-kDa catecholamineregulatedprotein: implications in central nervous system disorders. Cell Stress Chaperones 2009; 14: 555-67.
21. Xia Q, Liao L, Cheng D, et al. Proteomic identification of novelproteins associated with Lewy bodies. Front Biosci 2008; 13: 3850-6.
22. Martins-de-Souza D, Gattaz WF, Schmitt A, et al. Proteomicanalysis of dorsolateral prefrontal cortex indicates the involvementof cytoskeleton, oligodendrocyte, energy metabolism and newpotential markers in schizophrenia. J Psychiatr Res 2009; 43:978-86.
23. Martins-de-Souza D, Gattaz WF, Schmitt A, et al. Proteome analysis of schizophrenia patients Wernicke's area reveals anenergy metabolism dysregulation. BMC Psychiatry 2009; 9: 17.
24. Prabakaran S, Swatton JE, Ryan MM, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684-97.
25. Beasley CL, Pennington K, Behan A, et al. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders:evidence for disease-associated changes. Proteomics 2006; 6:3414-25.
26. English JA, Dicker P, Föcking M, et al. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009; 9: 3368-82.
27. Hazlett EA, Buchsbaum MS, Byne W, et al. Three-dimensionalanalysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am J Psychiatry 1999;156: 1190-9.
28. Tamminga CA, Thaker GK, Buchanan R, et al. Limbic systemabnormalities identified in schizophrenia using positron emissiontomography with fluorodeoxyglucose and neocortical alterationswith deficit syndrome. Arch Gen Psychiatry 1992; 49: 522-30.
29. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: apossible linkage to dopamine. J Neurochem 2002; 83: 1241-51.
30. Martins-de-Souza D, Dias-Neto E, Schmitt A, et al. Proteomeanalysis of schizophrenia brain tissue. World J Biol Psychiatry 2010; 11(2): 110-20.
31. Martins-de-Souza D, Harris LW, Guest PC, et al. The role of proteomicsin depression research. Eur Arch Psychiatry Clin Neurosci 2010; 260: 499-506.
32. Huang JT, Wang L, Prabakaran S, et al. Independent proteinprofilingstudies show a decrease in apolipoprotein A1 levels inschizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 2008; 13(12): 1118-28.
33. Levin Y, Wang L, Schwarz E, et al. Global proteomic profilingreveals altered proteomic signature in schizophrenia serum. Mol Psychiatry 2009; 15: 1088-100.
34. Prabakaran S, Wengenroth M, Lockstone HE, et al. 2-D DIGEanalysis of liver and red blood cells provides further evidence foroxidative stress in schizophrenia. J Proteome Res 2007; 6: 141-9.
35. Kultima K, Scholz B, Alm H, et al. Normalization and expressionchanges in predefined sets of proteins using 2D gel electrophoresis:a proteomic study of L-DOPA induced dyskinesia in an animalmodel of Parkinson's disease using DIGE. BMC Bioinformatics 2006; 7: 475.
36. Domenici E, Wille DR, Tozzi F, et al. Plasma Protein Biomarkersfor Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections. PLoS ONE 2010; 5(2): e9166.
37. Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci 2007; 8: 803-8.
38. Jang SW, Okada M, Sayeed I, et al. Gambogic amide, a selectiveagonist for TrkA receptor that possesses robust neurotrophic activity,prevents neuronal cell death. Proc Natl Acad Sci USA 2007;104(41): 16329-34.
39. Faber R, Trimble MR. Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord 1991; 6(4):293-303.
40. Lee CS, Kang KR, Lee JY, et al. Proteomic Analysis of Rat Brains Following Exposure to Electroconvulsive Therapy. J Korean MedSci 2009; 24: 132-7.
41. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33: 637-68.
42. Rothermundt M, Falkai P, Ponath G, et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004; 9: 897-9.
43. Yaffe MB, Rittinger K, Volinia S, et al. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 1997; 91: 961-71.
44. Urschel S, Bassermann F, Bai RY, et al. Phosphorylation of Grb10regulates its interaction with 14-3-3. J Biol Chem 2005; 280:16987-93.
45. Bell R, Munro J, Russ C, et al. Systematic screening of the 14-3-3eta (n) chain gene for polymorphic variants and case-control analysis in schizophrenia. Am J Med Genet 2000; 96: 736-43.
46. Vawter MP, Barrett T, Cheadle C, et al. Application of cDN Amicroarrays to examine gene expression differences in schizophrenia. Brain Res Bull 2001; 55: 641-50.
47. Wong AH, Macciardi F, Klempan T, et al. Identification of candidate genes for psychosis in rat models, and possible association between schizophrenia and the 14-3-3eta gene. Mol Psychiatry 2003;8: 156-66.
48. Rohlff C. Proteomics in molecular medicine: applications in central nervous systems disorders. Electrophoresis 2000; 21: 1227-34.
49. Valastro B, Dekundy A, Krogh M, et al. Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. J Neurochem 2007; 102: 1395-409.
50. Jakob U, Gaestel M, Engel K, et al. Small heat shock proteins are molecular chaperones. J Biol Chem 1993; 268: 1517-20.
51. Schulze C, Firth JA. Immunohistochemical localization of adherens junction components in blood-brain barrier microvessels of the rat. J Cell Sci 1993; 104(3): 773-82.
52. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protectsmice against 6-hydroxydopamine and scavenges hydroxyl freeradicals in vitro. Brain Res 1994; 657: 207-13.
53. Yoshikawa T, Minamiyama Y, Naito Y, et al. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994; 62:1034-8.
54. Sawada H, Ibi M, Kihara T, et al. Dopamine D2-type agonistsprotect mesencephalic neurons from glutamate neurotoxicity:mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998; 44: 110-9.
55. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12(10): 366-75.
56. Scholz B, Svensson M, Alm H, et al. Striatal Proteomic Analysis Suggests that First L-Dopa Dose Equates to Chronic Exposure. PLoS ONE 2008; 3(2): e1589.
57. Rojo AI, Montero C, Salazar M, et al. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Eur J Neurosci 2006; 24(7): 1874-84.
58. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80.
59. Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001; 2: 325-34.
60. Zhang X, Zhou JY, Chin MH, et al. Region-Specific Protein Abundance Changes in the Brain of MPTP-Induced Parkinson's Disease Mouse Model. J Proteome Res 2010; 9: 1496-509.
61. Hulley P, Schachner M, Lubbert H. L1 neural cell adhesion molecule is a survival factor for fetal dopaminergic neurons. J Neurosci Res 1998; 53: 129-34.
62. Loers G, Chen S, Grumet M, et al. Signal transduction pathways implicated in neural recognition molecule L1 triggered neuroprotection and neuritogenesis. J Neurochem 2005; 92: 1463-76.
63. Maness PF, Schachner M. Neural recognition molecules of the immunoglobulin superfamily: Signaling transducers of axonguidance and neuronal migration. Nat Neurosci 2007; 10: 19-26.
64. Law JW, Lee AY, Sun M, et al. Decreased anxiety, altered placelearning, and increased CA1 basal excitatory synaptic transmission in mice with conditional ablation of the neural cell adhesion moleculeL1. J Neurosci 2003; 23: 10419-32.
65. Diedrich M, Mao L, Bernreuther C, et al. Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenicmice. Proteomics 2008; 8: 1266-75.
66. Chin MH, Qian WJ, Wang H, et al. Mitochondrial Dysfunction, Oxidative Stress, and Apoptosis Revealed by Proteomic and Transcriptomic Analyses of the Striata in Two Mouse Models of Parkinson'sDisease. J Proteome Res 2008; 7: 666-77.
67. Park HJ, Lim S, Joo WS, et al. Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriataldopaminergic system in the rat Parkinson's disease model. Exp Neurol 2003; 180: 93-8.
68. Ha JY, Lee SH, Yin CS, et al. The effect of manual acupuncture therapy on symptoms of the patients with idiopathic Parkinson's disease. J Korean Orient Med 2003; 24: 172-83.
69. Kang JM, Park HJ, Choi YG, et al. Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model. Brain Res 2007; 1131: 211-9.
70. Eng ML, Lyons KE, Greene MS, et al. Open-label trial regardingthe use of acupuncture and yin tui na in Parkinson's disease outpatients:A pilot study on efficacy, tolerability, and quality of life. J Altern Complemen Med 2006; 12: 395-9.
71. Cristian A, Katz M, Cutrone E, et al. Evaluation of acupuncture in the treatment of Parkinson's disease: A double-blind pilot study. Mov Disord 2005; 20: 1185-8.
72. Jeon S, Kim YJ, Kim ST, et al. Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson'sdisease mouse model. Proteomics 2008; 8: 4822-32.
73. Ji B, La Y, Gao L, et al. A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J Proteome Res 2009; 8(7):3633-41.
74. Freedman R. Schizophrenia. N Engl J Med 2003; 349(18): 1738-49.
75. Lin ED, Lee NJ, Slack K, et al. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology 2006; 51: 1129-36.
76. Citrome L, Reist C, Palmer L, et al. Dose trends for secondgeneration antipsychotic treatment of schizophrenia and bipolardisorder. Schiz Res 2009; 108: 238-44.
77. Konarzewska B, Wolłczyński S, Szulc A, et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009; 34: 129-39.
78. Kashem MA, Ummehany R, Ukai W, et al. Effects of typical(haloperidol) and atypical (risperidone) antipsychotic agents onprotein expression in rat neural stem cells. Neurochem Int 2009;55: 558-65.
79. Ji B, Zhang Z, Zhang M, et al. Differential expression profiling of the synaptosome proteome in a rat model of antipsychotic resistance. Brain Res 2009; 1295: 170-8.
80. Karry R, Klein E, Shachar DB. Mitochondrial complex I subunitsexpression is altered in schizophrenia: a postmortem study. BiolPsychiatry 2004; 55: 676-84.
81. Carlsson A. The current status of the dopamine hypothesis ofschizophrenia. Neuropsychopharmacology 1988; 1: 179-86.
82. Coyle JT, Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 2004; 59: 491-515
83. Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamineto glutamate and back. Curr Med Chem 2004; 11: 267-77.
84. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
85. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
86. Paulson L, Martin P, Ljung E, et al. Proteome analysis after coadministration of clozapine or haloperidol to MK-801-treated rats. J Neural Transm 2007; 114: 885-91.
87. Behrens S, Gattaz WF. MK-801 induced stereotypes in rats are decreased by haloperidol and increased by diazepam. J Neural Transm Gen Sect 1992; 90: 219-24.
88. Hoffman DC. Typical and atypical neuroleptics antagonize MK-801- induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 1992; 89: 1-10.
89. Chen ML, Chen DH. Comparative proteome analysis revealed up regulation of transthyretin in rat brain under chronic clozapine treatment. J Psychiat Res 2007; 41: 63-8.
90. Gaetani S, Bellovino D, Apreda M, et al. Hepatic synthesis, maturation and complex formation between retinal-binding protein and transthyretin. Clin Chem Lab Med 2002; 40: 1211-20.
91. Palha JA. Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med 2002; 40: 1292-300.
92. Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA 1998;95: 7240-4.
93. Corena-McLeod MP, Oliveros A, Charlesworth C, et al. Paliperidoneas a mood stabilizer: A pre-frontal cortex synaptoneurosomalproteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res2008; 1233: 8-19.
94. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39.
95. Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of ratseroton in and norepinephrine neurons. Psychopharmacology 2007;194: 63-72.
96. McKay R. Asymmetry, stem cells and the emergence of function. Clin Neurosci Res 2001; 1: 183-6.
97. Wakade CG, Mahadik SP, Waller JL, et al. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 2002; 69:72-9.
98. Ukai W, Ozawa H, Tateno N, et al. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediatedsignal changes by haloperidol. J Neural Transm 2004; 111: 667-81.
99. Kurosawa S, Hashimoto E, Ukai W, et al. Olanzapine potentiatesneuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins. J Neural Transm 2007; 114: 1121-8.
100. Yan Q, Sage EH. SPARC, a matrixcellular glyprotein with importantbiological functions. J Histochem Cytochem 1999; 47: 1495-505.
101. Motamed K, Sage EH. SPARC inhibits endothelial cell adhesionbut not proliferation through a tyrosine phosphorylation-dependentpathway. J Cell Biochem 1998; 70: 543-5.
102. O'Brien E, Dedova I, Duffy L, et al. Effects of chronic risperidonetreatment on the striatal proteinprofiles in rats. Brain Res 2006;1113: 24-32.
103. Wong AH, Van Tol HH. Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav Rev 2003; 27(3): 269-306.
104. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanismof action of atypicalantipsychotic drugs and the neurobiology ofschizophrenia. CNS Drugs 2006; 20(5): 389-409.
105. Huang XF, Han M, Huang X, et al. Olanzapine differentially affects5-HT2Aand2C receptor mRNA expression in the rat brain. Behav Brain Res 2006; 171(2): 355-62.
106. Green W, Patil P, Marsden CA, et al. Treatment with olanzapineincreases cell proliferation in the subventricular zone and prefrontalcortex. Brain Res 2006; 1070(1): 242-5.
107. Pillai A, Mahadik SP. Differential effects of haloperidol and olanzapineon the expression of erythropoietin and its receptor in rathippocampus and striatum. J Neurochem 2006; 98(5): 1411-22.
108. Halim ND, Weickert CS, McClintock BW, et al. Effects of chronichaloperidol and clozapine treatment on neurogenesis in the adult rathippocampus. Neuropsychopharmacology 2004; 29(6): 1063-9.
109. Dwyer DS, Lu XH, Bradley RJ. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res 2003; 971(1): 31-9.
110. Ma D, Chan MK, Lockstone HE, et al. Antipsychotic Treatment Alters Protein Expression Associated with Presynaptic Function and Nervous System Development in Rat Frontal Cortex. J ProteomeRes 2009; 8: 3284-97.
111. Tosato S, Dazzan P, Collier D. Association between the neuregulin1 gene and schizophrenia: a systematic review. Schizophr Bull 2005; 31(3): 613-7.
112. Rushlow WJ, Seah YH, Belliveau DJ, et al. Changes in calcineurinexpression induced in the rat brain by the administration of antipsychotics. J Neurochem 2005; 94(3): 587-96.
113. Thomas EA. Molecular profiling of antipsychotic drug function:convergent mechanisms in the pathology and treatment of psychiatric disorders. Mol Neurobiol 2006; 34(2): 109-28.
114. Saviouk V, Moreau MP, Tereshchenko IV, et al. Association of synapsin 2 with schizophrenia in families of Northern Europeanancestry. Schizophr Res 2007; 96(1-3): 100-11.
115. Koh HY, Kim D, Lee J, et al. Deficits in social behavior and sensorimotorgating in mice lacking phospholipase C beta1. GenesBrain Behav 2008; 7(1): 120-8.
116. Anastasio NC, Johnson KM. Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration inthe developing rat. J Neurochem 2008; 104(5): 1210-8.
117. Dai Y, Wei Z, Sephton CF, et al. Haloperidol induces the nucleartranslocation of phosphatidylinositol 3'-kinase to disrupt Aktphosphorylation in PC12 cells. J Psychiatry Neurosci 2007; 32(5):323-30.
118. Singh RK, Shi J, Zemaitaitis BW, et al. Olanzapine increasesRGS7 protein expression via stimulation of the Janus tyrosinekinase-signal transducer and activator of transcription signalingcascade. J Pharmacol Exp Ther 2007; 322(1): 133-40.
119. Lee JY, Lee JH, Moon YW, et al. Proteomic analysis of lithiuminducedgene expression in the rat hypothalamus. Int J Neurosci 2009; 119(9): 1267-81.
120. Elashoff M, Higgs BW, Yolken RH, et al. Meta-analysis of 12genomic studies in bipolar disorder. J Mol Neurosci 2007; 31: 221-43.
121. McQuillin A, Rizig M, Gurling HM. A microarray gene expressionstudy of the molecular pharmacology of lithium carbonate onmouse brain mRNA to understand the neurobiology of mood stabilizationand treatment of bipolar affective disorder. PharmacogenetGenomics 2007; 17: 605-17.
122. Agarwal-Mawal A, Qureshi HY, Cafferty PW, et al. 14-3-3 connectsglycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. J Biol Chem 2003;278: 12722-8.
123. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: F.E. Bloom and D.J. Kupfer, Editors, Psychopharmacology. The Fourth Generation of Progress Raven Press New YorkUSA 1995; 933-44.
124. Daniela C, Silvia M, Hubert A, et al. Proteomic analysis of rat cortical neurons after fluoxetine treatment. Brain Res 2007;1135(2): 41-51.
125. Fuller RW, Wong DT, Robertson DW. Fluoxetine, a selectiveinhibitor of serotonin uptake, Med Res Rev 1991; 11: 17-34.
126. Khawaja X, Xu J, Liang JJ, et al. Proteomic Analysis of ProteinChanges Developing in Rat Hippocampus After Chronic Antidepressant Treatment: Implications for Depressive Disorders and FutureTherapies. J Neurosci Res 2004; 75: 451-60.
127. Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressanttreatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
128. Lucia C, Miriam V, Chiara P, et al. Proteomic analysis of rat hippocampusand frontal cortex after chronic treatment with fluoxetineor putative novel antidepressants: CRF1 and NK1 receptor antagonists. Eur Neuropsychopharmacol 2006; 16: 521-37.
129. Zobel AW, Nickel T, Kqnzel HE, et al. Effects of the high-affinitycorticotropinreleasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000; 34: 171-81.
130. Adell A. Antidepressant properties of substance P antagonists:relationship to monoaminergic mechanisms? Curr Drug Targets CNS Neurol Disord 2004; 3: 113-21.491-515.
131. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-basedguidelines for treating depressive disorders with antidepressants: arevision of the 2000 British Association for Psychopharmacologyguidelines. J Psychopharmacol 2008; 22: 343-96.
132. Ghaemi SN. Why antidepressants are not antidepressants: STEPBD, STARD, and the return of neurotic depression. Bipolar Disord 2008; 10(8): 957-68.
133. Montgomery SA. Why do we need new and better antidepressants? Int Clin Psychopharmacol 2006; 21: S1-S10.
134. Piubelli1 C, Vighini M, Mathé AA, et al. Escitalopram modulatesneuron-remodelling proteins in a rat gene-environment interactionmodel of depression as revealed by proteomics. Part I: geneticbackground. Int J Neuropsychopharmacol 2010; 8: 1-38.
135. Cassimeris L. The oncoprotein 18/stathmin family of microtubuledestabilizers. Curr Opin Cell Biol 2002; 14:18-24.
136. Katayama T, Hattori T, Yamada K, et al. Role of the PACAPPAC1-DISC1 and PACAP-PAC1-stathmin1 systems in schizophreniaand bipolar disorder: novel treatment mechanisms? Pharmacogenomics 2009; 10: 1967-78.
137. Carboni L, Vighini M, Piubelli C, et al. Proteomic analysis of rathippocampus and frontal cortex after chronic treatment withfluoxetine or putative novel antidepressants: CRF1 and NK1 receptorantagonists. Eur Neuropsychopharmacol 2006; 16(7): 521-37.
138. Hutchinson TH, Mahshid Y, Jonsson R, et al. Proteomic analysis ofphospholipidosis in citalopram treated U937 cells - support for thecholesterol biosynthesis hypothesis. Toxicol In Vitro 2008; 22:1198-204.
139. McHugh PC, Rogers GR, Loudon B, et al. Proteomic analysis ofembryonic stem cell-derived neural cells exposed to the antidepressantparoxetine. J Neurosci Res 2008; 86: 306-16.
140. Nakatani N, Ohnishi T, Iwamoto K, et al. Expression analysis ofactin-related genes as an underlying mechanism for mood disorders. Biochem Biophys Res Commun 2007; 352: 780-6.
141. Law AJ, Harrison PJ. The distribution and morphology of prefrontalcortex pyramidal neurons identified using anti-neurofilamentantibodies SMI32, N200 and FNP7. Normative data and a comparisonin subjects with schizophrenia, bipolar disorder or major depression. J Psychiatr Res 2003; 37: 487-99.
142. Miguel-Hidalgo JJ, Dubey P, Shao Q, et al. Unchanged packingdensity but altered size of neurofilament immunoreactive neuronsin the prefrontal cortex in schizophrenia and major depression. Schizophr Res 2005; 76: 159-71.
143. Ferrero AJ, Cereseto M, Sifonios LL, et al. Cytoskeleton of hippocampalneurons as a target for valproic acid in an experimentalmodel of depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1419-28.
144. Guest PC, Knowles MR, Molon-Noblot S, et al. Mechanisms of action of the antidepressants fluoxetine and the substance P antagonistL-000760735 are associated with altered neurofilamentsand synaptic remodeling. Brain Res 2004; 1002: 1-10.
145. Vaidya VA, Terwilliger RZ, Duman RS. Alterations in heavy andlight neurofilament proteins in hippocampus following chronicECS administration. Synapse 2000; 35: 137-43.
146. Bianchi M, Hagan JJ, Heidbreder CA. Neuronal plasticity, stressand depression: involvement of the cytoskeletal microtubular system? Curr Drug Targets CNS Neurol Disord 2005; 4: 597-611.
147. Kamada H, Saito T, Hatta S, et al. Alterations of tubulin functioncaused by chronic antidepressant treatment in rat brain. Cell MolNeurobiol 1999; 19: 109-17.
148. Yang C, Wang G, Wang H, et al. Cytoskeletal alterations in rathippocampus following chronic unpredictable mild stress and reexposureto acute and chronic unpredictable mild stress. BehavioralBrain Res 2009; 205: 518-24.
149. Bown C, Wang JF, MacQueen G, et al. Increased temporal cortexER stress proteins in depressed subjects who died by suicide. Neuropsychopharmacology 2000; 22: 327-32.
150. Chen B, Wang JF, Young LT. Chronic valproate treatment increasesexpression of endoplasmic reticulum stress proteins in therat cerebral cortex and hippocampus. Biol Psychiatry 2000; 48:658-64.
151. Shao L, Sun X, Xu L, et al. Mood stabilizing drug lithium increasesexpression of endoplasmic reticulum stress proteins in primary culturedrat cerebral cortical cells. Life Sci 2006; 78: 1317-23.
152. Park S, Lee J. Proteomic analysis to identify early molecular targetsof pregabalin in C6 glial cells. Cell Biol Int 2010; 34: 27-33.
153. Wu L, Peng J, Wei C, et al. Characterization, using comparativeproteomics, of differentially expressed proteins in the hippocampusof the mesial temporal lobe of epileptic rats following treatmentwith valproate. Amino Acids 2010; 40(1): 221-38.
154. Moshe SL. Seizures in the developing brain. Neurology 1993; 43:S3-S7.
155. Leite JP, Cavalheiro EA. Effects of conventional antiepilepticdrugs in a model of spontaneous recurrent seizures in rats. EpilepsyRes 1995; 20(2): 93-104.
156. Landmark CJ. Targets for antiepileptic drugs in the synapse. MedSci Monit 2007; 13(1): RA1-RA7.
157. Liu XY, Yang JL, Chen LJ, et al. Comparative proteomics andcorrelated signaling network of rat hippocampus in the pilocarpinemodel of temporal lobe epilepsy. Proteomics 2008; 8(3): 582-603.
158. Greene ND, Bamidele A, Choy M, et al. Proteome changes associatedwith hippocampal MRI abnormalities in the lithium pilocarpine-induced model of convulsive status epilepticus. Proteomics 2007; 7(8): 1336-44.
159. Frizzo ME, Dall'Onder LP, Dalcin KB, et al. Riluzole enhancesglutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 2004; 24: 123-8.
160. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence ofriluzole efficacy in antidepressant-treated patients with residual depressivesymptoms. Biol Psychiatry 2007; 61: 822-5.
161. Zarate Jr CA, Quiroz JA, Singh JB, et al. An open-label trial of theglutamate-modulating agent riluzole in combination with lithiumfor the treatment of bipolar depression. Biol Psychiatry 2005; 57:430-2.
162. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptorsas a new approach to treat schizophrenia: a randomized phase2 clinical trial. Nat Med 2007; 13: 1102-7.
163. Fatemi SH, Reutiman TJ, Folsom TD, et al. Chronic olanzapinetreatment causes differential expression of genes in frontal cortexof rats as revealed by DNA microarray technique. Neuropsychopharmacology 2006; 31: 1888-99.
164. Yazlovitskaya EM, Edwards E, Thotala D, et al. Lithium treatmentprevents neurocognitive deficit resulting from cranial irradiation. Cancer Res 2006; 66: 11179-86.
165. Malcangio M, Lessmann V. A common thread for pain and memorysynapses? Brain-derived neurotrophic factor and trkB receptors.Trends Pharmacol Sci 2003; 24(3): 116-21.
166. Kang H, Schuman EM. A requirement for local protein synthesis inneurotrophin-induced hippocampal synaptic plasticity. Science 1996; 273(5280): 1402-6.
167. Sanchez AL, Matthews BJ, Meynard MM, et al. BDNF increasessynapse density in dendrites of developing tectal neurons in vivo. Development 2006; 133(13): 2477-86.
168. Yin Y, Edelman GM, Vanderklish PW. The brain-derived neurotrophicfactor enhances synthesis of Arc in synaptoneurosomes. Proc Natl Acad Sci USA 2002; 99(4): 2368-73.
169. Takei N, Inamura N, Kawamura M, et al. Brain-derived neurotrophicfactor induces mammalian target of rapamycin-dependent localactivation of translation machinery and protein synthesis in neuronaldendrites. J Neurosci 2004; 24(44): 9760-9.
170. Schratt GM, Nigh EA, Chen WG, et al. BDNF regulates the translationof a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinasedependent pathway duringneuronal development. J Neurosci 2004; 24(33): 7366-77.
171. Willis D, Li KW, Zheng JQ, et al. Differential transport and localtranslation of cytoskeletal, injuryresponse, and neurodegenerationprotein mRNAs in axons. J Neurosci 2005; 25(4): 778-91.
172. Lujian L, Julie P, Tao X, et al. BDNF Induces WidespreadChanges in Synaptic Protein Content and Up-Regulates Componentsof the Translation Machinery: An Analysis Using High-Throughput Proteomics. J Proteome Res 2007; 6:1059-71.
173. Dwivedi Y, Rizavi HS, Conley RR, et al. Altered gene expressionof brain-derived neurotrophic factor and receptor tyrosine kinase Bin postmortem brain of suicide subjects. Arch Gen Psychiatry 2003;60: 804-15.
174. Karege F, Vaudan G, Schwald M, et al. Neurotrophin levels inpostmortem brains of suicide victims and the effects of antemortemdiagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005;136: 29-37.
175. Altar CA, Whitehead RE, Chen R, et al. Effects of electroconvulsiveseizures and antidepressant drugs on brain-derived neurotrophicfactor protein in rat brain. Biol Psychiatry 2003; 54: 703-9.
176. Katoh-Semba R, Asano T, Ueda H, et al. Riluzole enhances expressionof brain-derived neurotrophic factor with consequent proliferationof granule precursor cells in the rat hippocampus. FASEBJ 2002; 16: 1328-30.
177. Lauterborn JC, Lynch G, Vanderklish P, et al. Positive modulationof AMPA receptors increases neurotrophin expression by hippocampaland cortical neurons. J Neurosci 2000; 20: 8-21.
178. Kozisek ME, Middlemas D, Bylund DB. The differential regulationof BDNF and TrkB levels in juvenile rats after four days of escitalopramand desipramine treatment. Neuropharmacology 2008; 54:251-7.
179. Gardell LR, Wang R, Ehrenfels C, et al. Multiple actions ofsystemic artemin in experimental neuropathy. Nat Med 2003; 9:1383-9.
180. Bennett DL, Boucher TJ, Armanini MP, et al. The glial cell linederivedneurotrophic factor family receptor components are differentiallyregulated within sensory neurons after nerve injury. J Neurosci 2000; 20: 427-37.
181. Boucher TJ, Okuse K, Bennett DL, et al. Potent analgesic effects ofGDNF in neuropathic pain states. Science 2000; 290: 124-7.
182. Ramer MS, Priestley JV, McMahon SB. Functional regeneration ofsensory axons into the adult spinal cord. Nature 2000; 403: 312-6.
183. Schwab ME. Neurobiology. Finding the lost target. Nature 2000;403: 257-60.
184. Baloh RH, Tansey MG, Lampe PA, et al. Artemin, a novel memberof the GDNF ligand family, supports peripheral and central neuronsand signals through the GFRα3-RET receptor complex. Neuron 1998; 21: 1290-302.
185. Park S. Artemin: Basic Science and Clinical Implication. Rev Analg 2008; 10: 23-32.
186. Park S, Hong YW. Transcriptional regulation of artemin is relatedto neurite outgrowth and actin polymerization in mature DRG neurons. Neurosci Lett 2006; 404: 61-6.
187. Wang Z, Gardell LR, Ossipov MH, et al. Pronociceptive actions ofdynorphin maintain chronic neuropathic pain. J Neurosci 2001; 21:1779-86.
188. Devor M, Seltzer Z. Textbook of Pain. London: Churchill Livingstone 1999.
189. Rose MA, Kam PC. Gabapentin: pharmacology and its use in painmanagement. Anaesthesia 2002; 57: 451-62.
190. N'Kaoua B, Veron AL, Lespinet VC, et al. Time course of cognitiverecovery after propofol anaesthesia: a level of processing approach. J Clin Exp Neuropsychol 2002; 6: 713-9.
191. Zhanga X, Liua Y, Fengb C, et al. Proteomic profiling of the insolublefractions in the rat hippocampus post-propofol anesthesia. Neurosci Lett 2009; 465: 165-70.
192. Bruijn LI, Krishnamurthy PK, Gallo JM. Distinct patterns oftau-dependent process formation in mammalian cell lines. Neuroreport 2004; 14: 2223-6.
193. Field MJ, Holloman EF, McCleary S, et al. Evaluation of gabapentinand S-(+)-3-isobutylgaba in a rat model of postoperative pain. JPharmacol Exp Ther 1997; 282: 1242-6.
194. Houghton AK, Lu Y, Westlund KN. S-(+)-3-isobutylgaba and itsstereoisomer reduces the amount of inflammation and hyperalgesiain an acute arthritis model in the rat. J Pharmacol Exp Ther 1998;28: 533-8.
195. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypothesesof gabapentin pharmacology. Epilepsy Res 1998; 29: 233-49.
196. Maneuf YP, Gonzalez MI, Sutton KS, et al. Cellular and molecularaction of the putative GABA-mimetic gabapentin. Cell Mol LifeSci 2003; 60: 742-50.
197. Horner PJ, Power AE, Kempermann G, et al. Proliferation anddifferentiation of progenitor cells throughout the intact adult ratspinal cord. J Neurosci 2000; 20: 2218-28.
198. Graeber MB, Tetzlaff W, Streit WJ, et al. Microglial cells but notastrocytes undergo mitosis following rat facial nerve axotomy. Neurosci Lett 1988; 85: 317-21.
199. Suter MR, Wen YR, Decosterd I, et al. Do glial cells control pain? Neuron Glia Biol 2007; 3: 255-68.
200. Garrison CJ, Dougherty PM, Kajander KC, et al. Staining ofglial fibrillary acidic protein (GFAP) in lumbar spinal cordincreases following a sciatic nerve constriction injury. Brain Res 1991; 565: 1-7.
201. Venter JC, Adams MD, Myers EW, et al. The sequence of thehuman genome. Science 2001; 291: 1304-51.
202. Delom F, Chevet E. Phosphoprotein analysis: from proteins toproteomes. Proteome Sci 2006; 4: 15.
203. Hunter T. Protein kinases and phosphatases: the yin and yang ofprotein phosphorylation and signaling. Cell 1995; 80: 225-36.
204. Gomez-Mancilla B, Marrer E, Kehren J, et al. Central nervoussystem drug development: An integrative biomarker approach towardindividualized medicine. NeuroRx 2010; 2: 683-95.
205. Deutsch EW, Lam H, http://www.nature.com/embor/journal/v9/n5/full/embor200856.html-a1
206. Aebersold R. PeptideAtlas: a resourcefor target selection for emerging targeted proteomics workflows. EMBO Rep 2008; 9: 429-34.
207. HUPO - the Human Proteome organization. A gene-centric HumanProteome project. Mol Cell Proteomics 2010; 9: 427-9.
208. Hochstrasser, D. Should the human proteome project be gene- or protein-centric? J Proteome Res 2008; 7: 5071.
209. Yoon H, Kim J. Tutorial on Drug Development for Central Nervous System. Interdisciplinary Bio Central 2010; 2: 1-5.
210. Hampel H, Blennow K, Shaw LM, et al. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010; 45: 30-40.